RD Innovation presents PULSE at a high-profile radiation research workshop
Representatives from RD Innovation (RDI), a key partner in the PULSE consortium, recently showcased the project and their research at the Advanced Technologies in Radiation Research workshop in the United States.
Space radiation research attracts new institutions
Joining the event held at the National Institute of Allergy and Infectious Diseases Conference Center in Rockville, Maryland, Prof. Svend Aage Engelholm and Sergei Pigarev introduced PULSE’s concept and consortium to experts in radiation research, medical radiation, and space radiation. Their presentation also shed light on RDI’s groundbreaking work in developing radioprotectants and radiomitigators tailored for the challenges of the space environment.
The workshop, organized by esteemed institutions, including the Radiation and Nuclear Countermeasures Program and the US National Cancer Institute, made history by welcoming the National Aeronautics and Space Administration (NASA) for the first time, underscoring the increasing significance of space radiation research.
PULSE project unveiled
PULSE, focusing on acoustic and magnetic-based bioprinting technology for crafting 3D cardiac models, captured the attention of American peers “who requested to be kept up to date with project achievements,” noted Svend and Sergei.
These cardiac models, designed to study the effects of space radiation and microgravity, aim to enhance radioprotection for terrestrial healthcare and long-term space missions.
Key takeaways: urgency, innovation, and scope
Reflecting on the workshop, Svend and Sergei emphasized three key takeaways: “a pressing need for more radioprotective agents for astronauts, a growing interest in efficient and animal-friendly testing platforms, and an expanding scope of radiation research into space.”
These insights and engaging discussions with fellow participants fuel PULSE’s mission to unravel the impact of space radiation and microgravity on organisms.
The contributions of RDI
Sven and Sergei also presented RDI studies in swine models of radiation-induced cutaneous radiation injuries (CRI). “There were several stimulating discussions on model systems designed to study tissue damage and the impact of protective agents.”
Finally, the consensus among participants underscored the importance of leveraging medical radiation experience to address space challenges.
Part of a consortium: advantages and opportunities
In the context of the PULSE project, RDI collaborates with multiple consortium members to explore the effects of their radioprotectants/radiomitigators on cardiac tissue damage induced by cosmic radiation and microgravity. “We will attempt to develop finished dosage forms of agents suitable for use in space, including onboard the International Space Station,” they stated.
Svend and Sergei highlighted the strategic advantage of being part of the PULSE project, providing RDI access to top-tier experts in space, radiation, microgravity, regenerative medicine, and biofabrication. “Eventually, PULSE will help us generate data and provide the exposure needed to get better acquainted with the European Space Agency (ESA) and NASA.”